679 Urinalysis CPR
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The Department of Veterans Affairs (VA), specifically the Tuscaloosa VA Medical Center, has awarded SYSMEX AMERICA, INC. a contract valued at $373,954.55 for Automated Urinalysis Analyzers. This award, made on May 13, 2026, is for a Cost-Per-Test (CPT) / Cost-Per-Reportable-Result (CPRR) lease for an integrated automated urinalysis system.
Scope of Work
The requirement is for two Automated Urinalysis Analyzers (a primary and a back-up) to conduct urinalysis tests. The lease includes all calibrators, quality controls, and associated consumables.
Contract & Timeline
- Type: Award Notice (under Multiple-Award Schedule Program, FSS Contract Number V797D-40235)
- Award Number: V797D-4023536C24726N0244
- Award Amount: $373,954.55
- Award Date: May 13, 2026
- Awardee: SYSMEX AMERICA, INC
- Contracting Office: Department of Veterans Affairs, VISN 7 Network Contracting Office, Duluth, GA
- Period of Performance: Base Year (June 19, 2026 – June 18, 2027) plus four Option Periods, extending through June 18, 2031.
- Set-Aside: Sole Source
- Product Service Code: Q301 (Reference Laboratory Testing)
- NAICS Code: 621511
Justification for Sole Source
The award was made on a sole source basis due to an urgent and compelling need that would cause unacceptable delays if standard procedures were followed. Sysmex America, Inc. was identified as the sole manufacturer and proprietary rights holder of the required Urinalysis Solution. The formulation, calibration compatibility, and quality control parameters are unique to Sysmex and not available from third-party manufacturers. Market research confirmed no verified SDVOSB/VOSB firms capable of supplying the solution, and no equivalent alternatives were found. The use of a single-manufacturer platform ensures better cross-platform correlation, reduces result variability, minimizes validation burden, and supports standardization, operational efficiency, and clinical reliability.
Additional Notes
The agency will continue to monitor advancements in urinalysis platforms and OEM distribution models for future acquisitions. For inquiries, contact Chad Dinkins at chad.dinkins@va.gov or Chelsea Smith at chelsea.smith1@va.gov.